T-Cell Therapy Market to Reach $15.2 Billion, Globally, by 2032 at 18.3% CAGR: Allied Market Research

The growth of the global T-Cell therapy market is driven by rise in prevalence of cancer, Increase in demand of ideal therapeutics for treatment and Rise in awareness regarding T-cell therapy.


Portland, OR, June 15, 2023 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, “T-Cell Therapy Market by Therapy Type (CAR T-cell therapy and T-Cell Receptor (TCR)- Based), Indication(Lymphoma, Acute Lymphocytic Leukemia and Others) and by End User (Hospitals and Cancer Treatment Centers): Global Opportunity Analysis and Industry Forecast, 2023-2032 According to the report, the global dental lasers industry generated $2.8 billion in 2022, and is anticipated to generate $15.2 billion by 2032, witnessing a CAGR of 18.3% from 2022 to 2032. 

Download Sample Copy- https://www.alliedmarketresearch.com/request-sample/10893

Prime determinants of growth  

Growing prevalence of cancers such as lymphoma, acute lymphocytic leukemia, rise in awareness regarding gene therapy and increase in demand for ideal therapeutics for treatment drive the growth of the global T-Cell therapy market. However, side effects associated with cellular therapies such as cytokine release syndrome and neurotoxicity, which can limit its use and thus hamper the market growth. On the contrary, the growing healthcare infrastructure and adoption of such strategies product approval, agreement, and collaboration by key manufacturers are expected to offer remunerative opportunities for expansion of the T-Cell therapy market during the forecast period. 

Report coverage & details: 

Report Coverage  Details 
Forecast Period  2023–2032 
Base Year  2022 
Market Size in 2022  $2.8 billion 
Market Size in 2032  $15.2 billion 
CAGR  18.3% 
No. of Pages in Report  274
Segments covered  Therapy type, Indication, End Users, and Region. 
Drivers   Rise in the prevalence of cancer 

Increase in demand for ideal therapeutics for the treatment 

Rise in awareness regarding T-cell therapy 
Opportunities  Increase in R and D activities to develop T-cell therapeutics 
Restraints  High cost of T-cell therapies 

Strict government regulation for the approval of drugs 

Covid-19 Scenario 

  • Due to the COVID-19 pandemic and the subsequent global lockdowns, the T-Cell therapy market faced a downturn. 
  • However, as the global situation started ameliorating, the demand for efficient therapy, owing to prevailing cancer cases, was restored back. This, in turn, presented various growth opportunities for companies operating in the T-Cell therapy market. 

Procure Complete Report at 20% Discount (274 Pages PDF with Insights, Charts, Tables, and Figures)
https://www.alliedmarketresearch.com/checkout-final/t-cell-therapy-market

The CAR T-cell Therapy segment to maintain its leadership status throughout the forecast period 

Based on therapy type, the CAR T-Cell therapy segment held the highest market share in 2022, accounting for more than 90% of the global T-Cell therapy market revenue, and is estimated to maintain its leadership status throughout the forecast period, owing to exponential growth in the number of CAR T-cell therapy clinical trial and growth in the commitment of major key players in gene therapy. However, the T-Cell Receptor (TCR)- based segment is projected to manifest the highest CAGR of 25.8% from 2023 to 2032, owing to its positive results in treatment of solid malignancies. Furthermore, the growing focus of key players in expanding its application in treatment of different cancers such as melanoma is driving the growth. 

The Lymphoma segment to maintain its leadership status throughout the forecast period 

Based on indication, the Lymphoma segment held the highest market share in 2022, accounting for nearly two-thirds of the global T-Cell therapy market revenue, and is estimated to maintain its leadership status throughout the forecast period, owing to significant success of T-cell therapy in the treatment of blood cancers such as lymphoma. However, the others segment is projected to manifest the highest CAGR of 21.1% from 2023 to 2032, owing to growing interest in developing T-cell therapies for the treatment of diseases such as multiple myeloma and melanoma, which are often more difficult to treat with traditional therapies.  

The hospitals segment to maintain its lead position during the forecast period 

Based on end user, the hospitals segment held the largest market share in 2022, accounting for nearly three-fifths of the global T-Cell therapy market revenue, and is estimated to maintain its leadership status throughout the forecast period owing to presence of well-established infrastructure and advanced medical facilities necessary for conducting T-cell therapy. Additionally, the presence of experts in hospitals for performing T- cell therapy is expected to drive the growth. However, the cancer treatment centers segment is projected to manifest the highest CAGR of 18.9% from 2023 to 2032, owing to availability of a wide range of choice of treatment and increase in number of cancer centers in some developing nations. 

For Purchase Inquiry- https://www.alliedmarketresearch.com/purchase-enquiry/10893

North America to maintain its dominance by 2032 

Based on region, North America held the highest market share in terms of revenue in 2022, accounting for nearly two-thirds of the global T-Cell therapy market revenue, owing to rise in prevalence of cancer cases, growth in investment by private and public agencies and well-established research & commercialization base. However, the Asia-Pacific region is expected to witness the fastest CAGR of 21.7% from 2023 to 2032, and is likely to dominate the market during the forecast period, owing to rise in incidence of relapse cancer, increase in healthcare expenditure, growth in awareness about the importance of early detection and treatment of cancer and rise in adoption of gene therapy arena are expected to boost the market growth. 

Leading Market Players: - 

  • Novartis AG  
  • Autolus Therapeutics  
  • Caribou Biosciences, Inc  
  • Gilead Sciences, Inc.  
  • Immunocore Ltd.  
  • Celyad Oncology  
  • Cartesian Therapeutics, Inc.  
  • Johnson & Johnson  
  • Bristol-Myers Squibb Company  
  • Cellectis, Inc.  

The report provides a detailed analysis of these key players of the global T-Cell therapy market. These players have adopted different strategies such as product approval, agreement, and collaboration to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.   

Trending Research Reports of the Healthcare Industry:

Veterinary Imaging Market - Global Opportunity Analysis and Industry Forecast, 2021–2030
Varicose Vein Treatment Market- Global Opportunity Analysis and Industry Forecast, 2021–2030
Workplace Wellness Market - Global Opportunity Analysis and Industry Forecast, 2021–2030
Actinic Keratosis Treatment Market- Global Opportunity Analysis and Industry Forecast, 2021–2030
Surgical Retractor Market- Global Opportunity Analysis and Industry Forecast, 2021–2030

AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model):
AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.

Get an access to the library of reports at any time from any device and anywhere. For more details, follow the link: https://www.alliedmarketresearch.com/library-access

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high-quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll-Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com 
Web: https://www.alliedmarketresearch.com